BioSyent Pharma Inc., has initiated a voluntary recall of CIPROFLOXACIN INJECTION 2mg/ml on June 2/2010 to the hospital level. On May 29, 2010 the US FDA alerted healthcare professionals not to use Metronidazole, Ondansetron and Ciprofloxacin because of potential contamination. A Claris customer received a complaint of white matter in a bag of Metronidazole, and subsequent microbiological analysis identified the matter as a Cladosporium mould. Moulds of this type can cause infections in susceptible patients, such as immunocompromised individuals. Another customer complaint of white matter in a bag of Ondansetron was received, and that bag is currently under analysis. At this time, FDA is not aware of any reports of injuries due to administration of these products. Please note that the complaints received to date in the United States are for Metronidazole and Ondansetron. The FDA has decided to include Ciprofloxacin as this product is manufactured on the same production line.
Claris Lifescience Ltd., has distributed this product worldwide. In Canada, the product is only distributed to hospitals by BioSyent Pharma Inc. No export has been reported.